Leadership

CEO

Name Biography
James Jungkue Lee James Jungkue Lee founded Bridge Biotherapeutics Inc. in 2015 and currently serves as the CEO. After receiving his B.S and M.S. in Structural Biology from Seoul National University, he held various roles in research, research planning, and business development at LG Chem. After his tenure at LG Chem, James co-founded Crystal Genomics where he led fundraising and business development activities. In 2008, he founded Rex Bio and successfully developed an antibody treatment for pancreatic cancer.

SVP, Head of R&D

Name Biography
Sang-Uk Kang, Ph.D. Sang-Uk Kang serves as the Senior Vice President of Research and Development. After receiving his Ph.D. in Pharmacy at Seoul National University, he received his post-doctoral training at the National Cancer Institute in the US, focusing on the area of anti-cancer drugs and antibiotics. Sang-Uk was also involved in the discovery of anti-cancer and hepatitis C drugs at Rexahn and Sequoia, both biotech companies located in Maryland. Prior to joining Bridge Biotherapeutics, he served as a Senior Manager in new business development, medicinal chemistry, and CMC at Chemizon (now CMG Pharmaceuticals), Bukwang Pharmaceuticals, and Yuyu Pharmaceuticals.

SVP, Head of Clinical Development

Name Biography
Yong-Hee Lee, Ph.D. Yong-Hee Lee serves as the Senior Vice President of Clinical Development at Bridge Biotherapeutics. After receiving his Ph.D. in Pharmacy at Seoul National University, he conducted research on ocular drug delivery at the University of South California. Additionally, he focused on the pre-clinical development of new drugs at LG Chem and Ligand Pharmaceuticals after which he was responsible for the development of several new drugs, in various stages (pre-clinical and clinical) of development, at Ikaria (currently Mallinckrodt) and Pfizer.

VP, Medical Leadership

Name Biography
Angela Yum, MD, ABPN Angela Yum earned her M.D. from the College of Medicine at Seoul National University and completed specialty training in psychiatry at the University of Medicine and Dentistry of New Jersey (New Jersey Medical School). She started her industry career 12 years ago as a clinical research physician at Lilly then progressed to become the global clinical program leader at Boehringer Ingelheim. She also participated in numerous in-licensing reviews as a clinician team member. 

VP, Head of Translational Research

Name Biography
Gwanghee Lee, Ph.D. Gwanghee Lee serves as the Senior Vice President and Head of Translational Research. After receiving his B.S. and M.S. from Seoul National University, he earned his Ph.D. in Life Science from Washington University in St. Louis and completed his postdoctoral training at the National Institute of Health and Genentech in the U.S.. Prior to joining Bridge Biotherapeutics, he served as the Project Leader for the anti-cancer pipeline and as the Director of the Korea Research Institute at Sanofi.